Tissue physiology and the response to heat

References

• Vaupel P, Kallinowski F. Physiological effects of hyperthermia. Recent results in cancer research, C Streffer. Springer-Verlag, Heidelberg, Berlin 1987; 104: 71–109
   Google Scholar
• Patterson J, Strang R. The role of blood flow in hyperthermia. Int J Radiat Oncol Biol Phys 1979; 5: 235–241
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic micro-environment of human tumors: A review. Cancer Res 1989; 49: 6449–6465
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kelleher DK. Metabolic status and reaction to heat of normal and tumor tissue. Thermoradiotherapy and thermochemotherapy, MH Seegenschmiedt, P Fessenden, CC Vernon. Springer, BerlinHeidelberg, New York 1995; 1: 157–176
   Google Scholar
• Iwata K, Shakil A, Hur WJ, Makepeace CM, Griffin RJ, Song C. Tumour pO2 can be increased markedly by mild hyperthermia. Br J Cancer 1996; 74(suppl. XXVII)S217–S221
   Google Scholar
• Horsman MR. Overgaard J. Can mild hyperthermia improve tumor oxygenation?. Int J Hyperthermia 1997; 13: 141–147
   PubMed Web of Science ®Google Scholar
• Song CW, Patten MS, Chelstrom LM, Rhee JG, Levitt SH. Effect of multiple heatings on blood flow in RIF-1 tumours, skin and muscle of C3H mice. Int J Hyperthermia 1987; 3: 535–545
   PubMed Web of Science ®Google Scholar
• Gyldenhof B, Horsman MR, Overgaard J. Hyperthermia-induced changes in the vascularity and histopathology of a murine tumour and its surrounding normal tissue. Hyperthermic oncology, C Franconi, G Arcangeli, R Cavaliere. Tor Vergata, Rome 1996; II: 780–782
   Google Scholar
• Vaupel PW. Effects of physiological parameters on tissue response to hyperthermia: New experimental facts and their relevance to clinical problems. Hyperthermia Oncology 1992, EW Gerner, TC Cetas. Tucson Arizona Board of Regents, Tucson 1993; 17–23
   Google Scholar
• Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Dodge RK, Charles HC, Samulski TV, Proznitz LR, Dewhirst MW. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res 1996; 56: 5347–5350
   PubMed Web of Science ®Google Scholar
• Jones EL, Prosnitz LR, Dewhirst MW, Marcom PK, Hardenbergh PH, Marks LB, Brizel DM, Vujaskovic Z. Thermochemotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res 2004; 10: 4287–4293
   PubMed Web of Science ®Google Scholar
• Hetzel FW, Chopp M, Dereski MO. Variations in pO2 and pH response to hyperthermia: Dependence on transplant site and duration of treatment. Radiat Res 1992; 131: 152–156
   PubMed Web of Science ®Google Scholar
• Thrall DE, Gillette EL, Dewey WC. Effect of heat and ionizing radiation on normal and neoplastic tissue of the C3H mouse. Radiat Res 1975; 63: 363–377
   PubMed Web of Science ®Google Scholar
• Hill SA, Denekamp J. The effect of vascular occlusion on the thermal sensitization of a mouse tumor. Br J Radiol 1978; 51: 997–1002
   PubMed Web of Science ®Google Scholar
• Wallen CA, Colby TV, Stewart JR. Cell kill and tumor control after heat treatment with and without vascular occlusion in RIF-1 tumors. Radiat Res 1986; 106: 215–223
   PubMed Web of Science ®Google Scholar
• Voorhees WD, Babbs CF. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur J Cancer Clin Oncol 1982; 19: 1027–1033
   Google Scholar
• Horsman MR, Christensen KL, Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int J Hyperthermia 1989; 5: 123–136
   PubMed Web of Science ®Google Scholar
• Kalmus J, Okunieff P, Vaupel P. Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSaII tumors. Cancer Res 1990; 50: 15–19
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Prescott DM, Clegg S, Samulski TV, Page RL, Thrall DE, Leopold K, Rosner G, Acker JC, Oleson JR. The use of hydralazine to manipulate tumour temperatures during hyperthermia. Int J Hyperthermia 1990; 6: 971–983
   PubMed Web of Science ®Google Scholar
• Honess DJ, Hu DE, Bleehen NM. A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour. Int J Hyperthermia 1991; 7: 667–679
   PubMed Web of Science ®Google Scholar
• Prescott DM, Samulski TV, Dewhirst MW, Page RL, Thrall DE, Dodge RK, Oleson JR. Use of nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs. Int J Radiat Oncol Biol Phys 1992; 23: 377–385
   PubMed Web of Science ®Google Scholar
• Krossnes BK, Mella O, Dahl O. Use of the vasodilator sodium nitroprusside during local hyperthermia: Effects on tumor temperature and tumor response in a rat tumor model. Int J Radiat Oncol Biol Phys 1996; 36: 403–415
   PubMed Web of Science ®Google Scholar
• Poulson JM, Vujaskovic Z, Gaskin AA, La Rue SM, Meyer RE, Prescott DM, Samulski TV, Thrall DE, Dewhirst MW. Effect of calcitonin gene related peptide vs sodium nitroprusside to increase temperature in spontaneous canine tumours during local hyperthermia. Int J Hyperthermia 2004; 20: 477–489
   PubMed Web of Science ®Google Scholar
• Urano M, Montoya V, Booth A. Effect of hyperglycemia on the thermal response of murine normal and tumor tissue. Cancer Res 1983; 43: 453–455
   PubMed Web of Science ®Google Scholar
• Murray D, Milas L, Meyn RE. DNA damage produced by combined hyperglycemia and hyperthermia in two mouse fibrosarcoma tumors in vivo. Int J Radiat Oncol Biol Phys 1984; 10: 1679–1682
   PubMed Web of Science ®Google Scholar
• Osinsky SP, Bubnovskaja LN, Gusev AN. Enhancement of hyperthermic anti-tumor effect by selective alteration of tumour cells environment. Hyperthermic oncology, T Sugahara, M Saito. Taylor & Francis, London 1989; 1: 146–147
   Google Scholar
• Hiraoka M, Hahn GM. Changes in pH and blood flow induced by glucose, and their effects on hyperthermia with or without BCNU in RIF-1 tumours. Int J Hyperthermia 1990; 6: 97–103
   PubMed Web of Science ®Google Scholar
• Horsman MR, Sampson LE, Chaplin DJ. Overgaard J. The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia 1996; 12: 779–789
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 2001; 40: 497–503
   PubMed Web of Science ®Google Scholar
• Fisker RV, Horsman MR, Overgaard J. Hydralazine induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues. Cta Oncol 1991; 30: 641–647
   Google Scholar
• Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 1994; 29: 373–377
   PubMed Web of Science ®Google Scholar
• Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid. Int J Cancer 1995; 63: 119–123
   PubMed Web of Science ®Google Scholar
• Dark GD, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity towards tumor vasculature. Cancer Res 1997; 57: 1829–1834
   PubMed Web of Science ®Google Scholar
• Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by the combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998; 78: 439–445
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001; 77: 195–204
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Horsman MR. Vascular targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491–2499
   PubMed Web of Science ®Google Scholar
• Kallinowski F, Moehle R, Vaupel P. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor. Hyperthermic oncology, T Sugahara, M Saito. Taylor & Francis, London 1989; 1: 258–259
   Google Scholar
• Lin JC, Park HJ, Song CW. Combined treatment of IL-α and TNF-α potentiates the antitumour effect of hyperthermia. Int J Hyperthermia 1996; 12: 335–344
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Lee SH, Rood KL, Stewart MJ, Lyons JC, Lew YS, Park H, Song CW. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2000; 2: 555–560
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, Song CW. Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 2003; 19: 575–589
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Bjerkvig R, Dahl O. Vinblastine and hyperthermia target the neovasculature in BT4AN rat gliomas: Therapeutic implications of the vascular phenotype. Int J Radiat Oncol Biol Phys 2001; 51: 535–544
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumor effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001; 17: 508–519
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Schem BC, Mella O, Dahl O. The new tubulin inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys 2000; 46: 645–652
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Bjerkvig R, Mella O, Dahl O. Combretastatin A-4 and hyperthermia; A patent combination for the treatment of solid tumors. Radiother Oncol 2001; 60: 147–154
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001; 51: 1018–1024
   PubMed Web of Science ®Google Scholar
• Sakaguchi Y, Maehara Y, Baba H, Kusumoto T, Sugimachi K, Newman RA. Flavone acetic acid increases the antitumor effect of hyperthermia in mice. Cancer Res 1992; 52: 3306–3309
   PubMed Web of Science ®Google Scholar
• Maxwell RJ, Nielsen FU, Breidahl T, Stødkilde-Jørgensen H, Horsman MR. Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI. Int J Radiat Oncol Biol Phys 1998; 42: 891–894
   PubMed Web of Science ®Google Scholar
• Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiol 1977; 123: 511–514
   PubMed Web of Science ®Google Scholar
• Overgaard J, Nielsen OS. The role of tissue environmental factors on the kinetics and morphology of tumor cells exposed to hyperthermia. Ann NY Acad Sci 1980; 335: 254–280
   PubMedGoogle Scholar
• Overgaard J. Rationale and problems in the design of clinical trials. Hyperthermic oncology, J Overgaard. Taylor & Francis, London 1985; 2: 325–338
   Google Scholar
• Nielsen OS, Horsman M, Overggard J. A future for hyperthermia in cancer treatment?: An editorial comment. Eur J Cancer 2001; 37: 1587–1589
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. Overcoming tumour radioresistance resulting from hypoxia. Basic clinical radiobiology for radiation oncologists. 3rd ed, GG Steel. Edward Arnold, London 2002; 169–181
   Google Scholar
• Der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WC, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomized, multicentre trial. The Lancet 2000; 355: 1119–1125
   PubMed Web of Science ®Google Scholar
• Durand RE. Keynote address: The influence of microenvironmental factors on the activity of radiation and drugs. Int J Radiat Oncol Biol Phys 1991; 20: 253–258
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C, MacFall J, Rosner G, Samulski T, Gillette E, La Rue S. Hyperthermic treatment of malignant diseases: Current status and a view toward the future. Semin Oncol 1997; 24: 616–625
   PubMed Web of Science ®Google Scholar